BR112022017852A2 - Vacinas para herpes zoster compreendendo um agonista de tlr9 - Google Patents
Vacinas para herpes zoster compreendendo um agonista de tlr9Info
- Publication number
- BR112022017852A2 BR112022017852A2 BR112022017852A BR112022017852A BR112022017852A2 BR 112022017852 A2 BR112022017852 A2 BR 112022017852A2 BR 112022017852 A BR112022017852 A BR 112022017852A BR 112022017852 A BR112022017852 A BR 112022017852A BR 112022017852 A2 BR112022017852 A2 BR 112022017852A2
- Authority
- BR
- Brazil
- Prior art keywords
- herpes zoster
- tlr9 agonist
- vaccines
- tlr9
- agonist
- Prior art date
Links
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 title abstract 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 3
- 208000007514 Herpes zoster Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940029575 guanosine Drugs 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16771—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
VACINAS PARA HERPES ZOSTER COMPREENDENDO UM AGONISTA DE TLR9. A presente invenção refere-se a composições imunogênicas compreendendo um antígeno de glicoproteína E do vírus varicela zoster (VZV) e um agonista do receptor 9 do tipo toll (TLR9), tal como um oligonucleotídeo compreendendo um motivo de citidina-fosfo-guanosina (CpG) não metilado. As composições imunogênicas são adequadas para estimular uma resposta imune contra VZV em um indivíduo em necessidade das mesmas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062987243P | 2020-03-09 | 2020-03-09 | |
PCT/US2021/021544 WO2021183540A1 (en) | 2020-03-09 | 2021-03-09 | Shingles vaccines comprising a tlr9 agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017852A2 true BR112022017852A2 (pt) | 2022-11-01 |
Family
ID=77672121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017852A BR112022017852A2 (pt) | 2020-03-09 | 2021-03-09 | Vacinas para herpes zoster compreendendo um agonista de tlr9 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230061403A1 (pt) |
EP (1) | EP4117726A4 (pt) |
JP (1) | JP2023517597A (pt) |
KR (1) | KR20230013237A (pt) |
CN (1) | CN115768892A (pt) |
AU (1) | AU2021236059A1 (pt) |
BR (1) | BR112022017852A2 (pt) |
CA (1) | CA3174927A1 (pt) |
IL (1) | IL296283A (pt) |
MX (1) | MX2022011159A (pt) |
WO (1) | WO2021183540A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3241245A1 (en) * | 2021-12-23 | 2023-06-29 | Robert S. Janssen | Immunogenicity of a cpg-adjuvanted herpes zoster vaccine |
CN118085111A (zh) * | 2024-04-28 | 2024-05-28 | 天津中逸安健生物科技有限公司 | 一种融合蛋白gE-Fc及其在制备重组带状疱疹疫苗中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0109297D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
EP2901856B1 (en) * | 2004-06-15 | 2017-08-09 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
WO2007120368A2 (en) * | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
CN102517302A (zh) * | 2011-12-28 | 2012-06-27 | 中国人民解放军军事医学科学院野战输血研究所 | 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用 |
EP3041505A4 (en) * | 2013-09-05 | 2017-04-19 | Merck Sharp & Dohme Corp. | Methods of immunization with varicella zoster virus antigen |
EP3079717A1 (en) * | 2013-12-09 | 2016-10-19 | Bullet Biotechnology, Inc. | Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof |
US20190298824A1 (en) * | 2016-05-04 | 2019-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Albumin-binding immunomodulatory compositions and methods of use thereof |
EP3560512A4 (en) * | 2016-12-26 | 2020-07-22 | Mogam Institute for Biomedical Research | COMPOSITION OF VACCINE AGAINST ZONA |
CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
-
2021
- 2021-03-09 WO PCT/US2021/021544 patent/WO2021183540A1/en active Application Filing
- 2021-03-09 AU AU2021236059A patent/AU2021236059A1/en active Pending
- 2021-03-09 EP EP21767529.7A patent/EP4117726A4/en active Pending
- 2021-03-09 KR KR1020227034628A patent/KR20230013237A/ko unknown
- 2021-03-09 CN CN202180032671.4A patent/CN115768892A/zh active Pending
- 2021-03-09 CA CA3174927A patent/CA3174927A1/en active Pending
- 2021-03-09 BR BR112022017852A patent/BR112022017852A2/pt unknown
- 2021-03-09 JP JP2022554573A patent/JP2023517597A/ja active Pending
- 2021-03-09 MX MX2022011159A patent/MX2022011159A/es unknown
- 2021-03-09 US US17/910,334 patent/US20230061403A1/en active Pending
- 2021-03-09 IL IL296283A patent/IL296283A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021236059A1 (en) | 2022-11-03 |
KR20230013237A (ko) | 2023-01-26 |
JP2023517597A (ja) | 2023-04-26 |
IL296283A (en) | 2022-11-01 |
CA3174927A1 (en) | 2021-09-16 |
CN115768892A (zh) | 2023-03-07 |
EP4117726A4 (en) | 2024-03-27 |
EP4117726A1 (en) | 2023-01-18 |
WO2021183540A1 (en) | 2021-09-16 |
US20230061403A1 (en) | 2023-03-02 |
MX2022011159A (es) | 2022-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017852A2 (pt) | Vacinas para herpes zoster compreendendo um agonista de tlr9 | |
PE20152002A1 (es) | Composiciones y metodos para modular la expresion de ttr y vhb | |
ES2749627T3 (es) | Complejo que contiene oligonucleótido que tiene actividad inmunoestimulante y su uso | |
ES2562456T3 (es) | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes | |
BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
UY31280A1 (es) | Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada | |
BRPI0410702A (pt) | polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor | |
BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
UY38015A (es) | Composiciones inmunoestimulantes | |
MX2019007288A (es) | Composicion de vacuna para herpes zoster. | |
BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
Sandgren et al. | Understanding natural herpes simplex virus immunity to inform next‐generation vaccine design | |
AR103427A1 (es) | Vacuna contra la fiebre aftosa | |
BR112014023414A2 (pt) | vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos | |
MX2022010642A (es) | Vacunas contra coronavirus que comprenden un agonista de tlr9. | |
CL2023001826A1 (es) | Eliminación genómica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables | |
CL2022002456A1 (es) | Inmunización activa contra el tétanos, la difteria y la tos ferina. | |
BR112021025286A2 (pt) | Vacina contra o hiv com base em células t alogênicas para induzir a imunidade celular e humoral | |
ZA202104747B (en) | Novel trypanosomal vaccine | |
UY32876A (es) | Régimen de inmunización por sensibilización-refuerzo heteróloga | |
AR105539A1 (es) | Potenciamiento de la respuesta inmunológica en especies acuáticas | |
AR113950A1 (es) | Composiciones inmunoestimulantes | |
BR112018070126A8 (pt) | composição imunogênica, e, métodos para induzir uma resposta imune a um antígeno e uma proteção imune inata. | |
AR113949A1 (es) | Oligonucleótidos inmunoestimulantes |